Form 4: Amicus Therapeutics Executive Samantha Prout Reports Stock Transactions

Chief Accounting Officer of Amicus Therapeutics, Samantha Prout, reports multiple transactions involving company stock, including the acquisition of restricted stock units and stock options.

Summary

• Samantha Prout, Chief Accounting Officer at Amicus Therapeutics, reported several transactions involving the company's stock.
• On January 2, 2025, 3,443 shares were disposed of at a price of $9.31 per share.
• On January 3, 2025, 34,614 restricted stock units (RSUs) were acquired at no cost, and 8,275 shares were disposed of at $9.41 per share.
• Additionally, on January 3, 2025, 62,715 stock options were acquired with an exercise price of $9.41.
• On January 4, 2025, 1,297 shares were disposed of at $9.41 per share.
• Following these transactions, Ms. Prout beneficially owns 95,525 shares of common stock and 62,715 stock options.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions by an executive. There is no indication of positive or negative sentiment, it is a routine filing.

Positives

• The acquisition of 34,614 Restricted Stock Units (RSUs) at no cost indicates a potential long-term incentive for the executive.
• The acquisition of 62,715 stock options provides an opportunity for future gains if the stock price increases.

Negatives

• The disposal of 13,015 shares across multiple transactions may indicate a short-term profit-taking strategy by the executive.

Risks

• The disposal of shares by a key executive could be perceived negatively by the market.
• The vesting schedule of the RSUs and stock options could influence the executive's decisions regarding the company's stock.

Future Outlook

The vesting schedule of the RSUs and stock options will influence future transactions by the executive.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the trading activities of insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The vesting schedules for RSUs and stock options are typical for executive compensation packages in the biotech industry.
• The reported transactions are similar to those seen in other companies where executives receive equity-based compensation.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into executive sentiment and potential future stock movements.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Next Steps

• The executive's future transactions will be influenced by the vesting schedule of the RSUs and stock options.
• Further Form 4 filings will be made if there are additional transactions.

Key Dates

Keywords

Amicus Therapeutics, stock transactions, insider trading, Form 4, restricted stock units, stock options, Samantha Prout, executive compensation